celecoxib has been researched along with Experimental Neoplasms in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-carcinogenic markers in various experimental studies." | 7.88 | Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. ( Chandel, D; Sharaf, LK; Sharma, M; Shukla, G, 2018) |
| "Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice." | 7.72 | Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. ( Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L; Zhang, S, 2004) |
| "Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-carcinogenic markers in various experimental studies." | 3.88 | Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. ( Chandel, D; Sharaf, LK; Sharma, M; Shukla, G, 2018) |
| "Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice." | 3.72 | Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. ( Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L; Zhang, S, 2004) |
| "Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1." | 2.73 | Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007) |
| "Celecoxib is an effective inhibitor of COX-2, used in anti-inflammation." | 1.48 | Celecoxib Conjugated Fluorescent Probe for Identification and Discrimination of Cyclooxygenase-2 Enzyme in Cancer Cells. ( Cui, H; Du, J; Fan, J; Gurram, B; Li, H; Li, M; Peng, X; Wang, J; Xie, Y; Zhang, S, 2018) |
| "Celecoxib has also a possible involvement with redox homeostasis, because its administration caused significant changes in the activity of oxidative enzymes, such as catalase and superoxide dismutase." | 1.36 | Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. ( Acco, A; Ávila, TV; Bastos-Pereira, AL; Cadena, SM; Cristina da Silva de Assis, H; Donatti, L; Lugarini, D; Muscará, MN; Oliveira-Christoff, Ad; Pires, Ado R; Teixeira, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurram, B | 1 |
| Zhang, S | 2 |
| Li, M | 1 |
| Li, H | 1 |
| Xie, Y | 1 |
| Cui, H | 1 |
| Du, J | 1 |
| Fan, J | 1 |
| Wang, J | 2 |
| Peng, X | 1 |
| Sharaf, LK | 1 |
| Sharma, M | 1 |
| Chandel, D | 1 |
| Shukla, G | 1 |
| Ding, N | 1 |
| Cui, XX | 1 |
| Gao, Z | 1 |
| Huang, H | 1 |
| Wei, X | 1 |
| Du, Z | 1 |
| Lin, Y | 1 |
| Shih, WJ | 1 |
| Rabson, AB | 1 |
| Conney, AH | 1 |
| Hu, C | 1 |
| Zheng, X | 1 |
| Xiang, HG | 1 |
| Xie, X | 1 |
| Hu, FQ | 1 |
| Xiao, HB | 1 |
| Zhang, WJ | 1 |
| Chen, L | 1 |
| Balansky, R | 1 |
| Ganchev, G | 1 |
| Iltcheva, M | 1 |
| Nikolov, M | 1 |
| La Maestra, S | 1 |
| Micale, RT | 1 |
| D'Agostini, F | 1 |
| Steele, VE | 1 |
| De Flora, S | 1 |
| Ilhan, N | 1 |
| Gungor, H | 1 |
| Gul, HF | 1 |
| Eroksuz, H | 1 |
| Colby, JK | 1 |
| Klein, RD | 1 |
| McArthur, MJ | 1 |
| Conti, CJ | 1 |
| Kiguchi, K | 1 |
| Kawamoto, T | 1 |
| Riggs, PK | 1 |
| Pavone, AI | 1 |
| Sawicki, J | 1 |
| Fischer, SM | 1 |
| Maussang, D | 1 |
| Langemeijer, E | 1 |
| Fitzsimons, CP | 1 |
| Stigter-van Walsum, M | 1 |
| Dijkman, R | 1 |
| Borg, MK | 1 |
| Slinger, E | 1 |
| Schreiber, A | 1 |
| Michel, D | 1 |
| Tensen, CP | 1 |
| van Dongen, GA | 1 |
| Leurs, R | 1 |
| Smit, MJ | 1 |
| Bastos-Pereira, AL | 1 |
| Lugarini, D | 1 |
| Oliveira-Christoff, Ad | 1 |
| Ávila, TV | 1 |
| Teixeira, S | 1 |
| Pires, Ado R | 1 |
| Muscará, MN | 1 |
| Cadena, SM | 1 |
| Donatti, L | 1 |
| Cristina da Silva de Assis, H | 1 |
| Acco, A | 1 |
| Li, W | 1 |
| Jiang, HR | 1 |
| Xu, XL | 1 |
| Zhang, J | 1 |
| Liu, ML | 1 |
| Zhai, LY | 1 |
| Yu, L | 1 |
| Chen, M | 1 |
| Li, Z | 1 |
| Wen, J | 1 |
| Fu, J | 1 |
| Guo, D | 1 |
| Jiang, Y | 1 |
| Wu, S | 1 |
| Cho, CH | 1 |
| Liu, S | 1 |
| Lawson, KA | 1 |
| Simmons-Menchaca, M | 1 |
| Sun, L | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Li, N | 1 |
| Sood, S | 1 |
| Wang, S | 1 |
| Fang, M | 1 |
| Wang, P | 1 |
| Sun, Z | 1 |
| Yang, CS | 1 |
| Chen, X | 1 |
| Javle, MM | 1 |
| Cao, S | 1 |
| Durrani, FA | 1 |
| Pendyala, L | 1 |
| Lawrence, DD | 1 |
| Smith, PF | 1 |
| Creaven, PJ | 1 |
| Noel, DC | 1 |
| Iyer, RV | 1 |
| Rustum, YM | 1 |
| Masferrer, JL | 1 |
| Leahy, KM | 1 |
| Koki, AT | 1 |
| Zweifel, BS | 1 |
| Settle, SL | 1 |
| Woerner, BM | 1 |
| Edwards, DA | 1 |
| Flickinger, AG | 1 |
| Moore, RJ | 1 |
| Seibert, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
1 trial available for celecoxib and Experimental Neoplasms
| Article | Year |
|---|---|
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco | 2007 |
14 other studies available for celecoxib and Experimental Neoplasms
| Article | Year |
|---|---|
Celecoxib Conjugated Fluorescent Probe for Identification and Discrimination of Cyclooxygenase-2 Enzyme in Cancer Cells.
Topics: Animals; Celecoxib; Cell Survival; Cells, Cultured; Chlorocebus aethiops; Cyclooxygenase 2; Dose-Res | 2018 |
Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Carcinogens; | 2018 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvasta | 2014 |
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxy | 2014 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; C | 2015 |
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibi | 2016 |
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Transformation, Neoplastic | 2008 |
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.
Topics: Animals; Celecoxib; Cell Line; Cell Transformation, Viral; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2009 |
Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Body Weight; Catalase; Celecoxib; Cyclooxygenase 2; C | 2010 |
Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D | 2010 |
Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cispla | 2011 |
Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Interactions; Drug Therapy, Combin | 2004 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogen | 2005 |
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2000 |